Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter

Blood

Volumn 95, Issue 8, 2000, Pages 2536-2542

  Hagstrom, J Nathan ^b   Couto, Linda B ^b   Scallan, Ciaran ^b   Burton, Melissa ^b   McCleland, Mark L ^b   Fields, Paul A ^b   Arruda, Valder R ^b   Herzog, Roland W ^b   High, Katherine A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; BLOOD CLOTTING FACTOR 9; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADOLESCENT; ANIMAL CELL; ARTICLE; CYTOMEGALOVIRUS; ENHANCER REGION; GENE TRANSFER; HEMOPHILIA B; HUMAN; HUMAN CELL; HYBRID GENE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS GENE;

EID: 0034655597     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2536     Document Type: Article

References (39)

1. Ljung RCR. Can haemophilic arthropathy be prevented? Br J Haematol. 1998;101:215-219.
2. Ljung RCR. Prophylactic treatment in Sweden -overtreatment or optimal model? Haemophilia. 1998;4:409-412.
3. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999;5: 56-63.
4. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70.
5. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93: 14,082-14,087.
6. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-8108.
7. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3:306-312.
8. Ferrari FK, Xiao X, McCarty D, Samulski RJ New developments in the generation of Ad-free, high titer rAAV gene therapy vectors. Nat Med. 1997;3: 1295-1297.
9. Yao S-N, Smith KJ, Kurachi K. Primary myoblast-medialed gene transfer: persistent expression of human factor IX in mice. Gene Ther. 1994;1:99-107.
10. Arruda VR, Hagstrom JN, Herzog RW, et al. Factor IX synthesized in dog and human muscle cells has specific activity comparable to plasma-derived factor IX. Blood. 1998;92(suppl 1):2836.
11. Herzog RW, Hagstrom JN, Kung Z-H, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94:5804-5809.
12. Sambrook J, Fritsch EF, T. M: Molecular Cloning: A Laboratory Manual. 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press: 1989.
13. Nakai H, Herzog R, Hagstrom JN, et al. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 1998;91:4600-4607.
14. Kurachi S, Hitomi Y, Midori F, Kurachi K. Role of intron I in expression of the human factor IX gene. J Biol Chem. 1995;270:5276-5281.
15. Yoshitake S, Schach BG, Foster DC, Davie EW, Kuracki K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24:3736-3750.
16. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982;79:6461.
17. Muscat GEO, Kedes L Multiple 5′-flanking regions of the human αlaquo;-skeletal actin gene synergistically modulate muscle-specific expression. Mol Cell Biol. 1987;7:4089-4099.
18. Taylor A, Erba HP, Muscat GEO, Kedes L. Nucleotide sequence and expression of the human skeletal α-actin gene: evolution of functional regulatory domains. Genomics. 1988;3:323-336.
19. Marr JH, Ordahl CP. A conserved CATTCCT motif is required for skeletal muscle-specific activity of the cardiac troponin T gene promoter. Proc Natl Acad Sci U S A. 1988;85:6404-6408.
20. Marr JH, Antin PB, Cooper TA, Ordahl CP. Analysis of the upstream regions governing expression of the chicken cardiac troponin T-gene in embryonic cardiac and skeletal muscle cells J Cell Biol. 1988;107:573-585.
21. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1996;5: 938-945.
22. Walter J, You Q, Hagstrom JN, Sands M, High KA. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice. Proc Natl Acad Sci U S A. 1996; 93:3056-3061.
23. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. Rag-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869-877.
24. Herzog RW, High KA. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy. Thromb Haemost. 1999;82:540-546
25. Yew NS, Wysokenski DM, Wang KX, et al. Optimization of plasmid vectors for high-level expression in lung epithelial cells Hum Gene Ther. 1997;8:575-584.
26. Smith T, White B, Tolstoshev P, Kaleko M, McClelland A. Long-term in vivo expression and effective repeat delivery of a novel adenovirus vector containing a human factor IX minigene. Blood. 1995;86(suppl 1):945.
27. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-276.
28. Skarli M, Kiri A, Vrbova G, Lee CA, Goldspink G. Myosin regulatory elements as vectors for gene transfer by intramuscular injection Gene Ther. 1998;5:514-520.
29. Hauser MA, Amalfitano A, Kumar-Singh R, Hauschka SD, Chamberlain JS Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul Disord. 1997;7:277-283.
30. Donoviel DB, Shield MA, Buskin JN, Haugen HS, Clegg CH, Hauschka SD. Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol. 1996;16:1649-1658.
31. Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A. 1997;94:13,921-13,926.
32. Snyder RO, Spratt SK, Lagarde C, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 1997;8: 1891-1900.
33. Löser P, Jennings SG, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkB. J Virol. 1998; 72:180-190.
34. Dai Y, Roman M, Naviaux RK, Verma IM. Gene-therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A. 1992;89: 10,892-10,895.
35. Wang J-M, Zheng H, Sugahara Y, et al. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Hum Gene Ther. 1996;7:1743-1756.
36. Brennan KJ, Hardeman EC. Quantitative analysis of the human α-skeletal actin gene in transgenic mice. J Biol Chem. 1993;268:719-725.
37. Ernst H, Walsh K, Harrison CA, Rosenthal N. The myosin light chain enhancer and the skeletal actin promoter share a binding site for factors involved in muscle-specific gene expression. Mol Cell Biol. 1991;11:3735-3744.
38. Butler AJ, Ordahl CP: Poly(ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription. Mol Cell Biol. 1999;19:296-306.
39. MacLellan WR, Lee T-C, Schwartz RJ, Schneider MD. Transforming growth factor-β response elements of the skeletal α-actin gene. J Biol Chem. 1994;269:16,754-16,760.